Lead Manager/ | # of | Price Range | Dollar | SCOOP | ||
New Filings (Proposed Symbol) | Joint-Lead Managers | Shares | Low | High | Volume | Ratings |
Avantor (TBA) | Goldman Sachs/ J.P. Morgan | $100.00 | n.a. | |||
ShockWave Medical (SWAV) | Morgan Stanley/ BofA Merrill Lynch | $70.00 | n.a. | |||
Tortoise Acquisition (SHLL.U) (u) | Barclays/ Goldman Sachs/ UBS Investment Bank | 22.50 | $10.00 | $10.00 | $225.00 | n.a. |
n.a. (not available) | ||||||
TBA (to be announced) | ||||||
u – unit offering | ||||||
Postponed | ||||||
None | ||||||
Withdrawn | ||||||
None | ||||||
New Terms | ||||||
Avedro (AVDR) | BofA Merrill Lynch/ J.P. Morgan | 5.00 | $14.00 | $16.00 | $75.00 | S/O |
Cibus (CBUS) | Morgan Stanley/ BofA Merrill Lynch/ Piper Jaffray | 6.67 | $14.00 | $16.00 | $100.00 | S/O |
Hoth Therapeutics (HOTH) | Laidlaw & Company (UK) Ltd. | 1.25 | $5.50 | $6.50 | $7.50 | S/O |
IMAC Holdings (IMACW) | Dawson James Securities/ Cuttone | 1.70 | $0.00 | $0.00 | $0.00 | S/O |
Stealth BioTherapeutics (MITO) | Jefferies/ Evercore ISI/ BMO Capital Markets | 6.20 | $12.00 | $14.00 | $80.60 | S/O |
TCR2 Therapeutic (TCRR) | Jefferies/ Leerink Partners/ BMO Capital Markets | 5.00 | $14.00 | $16.00 | $75.00 | S/O |
S/O (Subscribers Only) | ||||||
IPOs Priced | Lead | Shares | Amount | Offer | Close | % |
Week of Feb. 4, 2019 | Manager(s) | Offered | Raised | Price | 2/8/19 | Change |
Gossamer Bio (GOSS) | BofA Merrill Lynch/ Leerink Partners/ Barclays/ Evercore ISI | 17.25 | $276.00 | $16.00 | $17.94 | 12.13% |
Wealthbridge Acquisition (HHHHU) (u) | Chardan | 5.00 | $50.00 | $10.00 | $10.03 | 0.30% |
Monocle Acquisition (MNCLU) (u) | Cowen/ Chardan | 15.00 | $150.00 | $10.00 | $10.02 | 0.20% |
RMG Acquisition (RMG.U) (u) | Deutsche Bank Securities | 20.00 | $200.00 | $10.00 | $10.00 | 0.00% |
Harpoon Therapeutics (HARP) | Citigroup/ Leerink Partners | 5.40 | $75.60 | $14.00 | $13.50 | -3.57% |
Alector (ALEC) | Morgan Stanley/ BofA Merrill Lynch/ Cowen/ Barclays | 9.25 | $175.75 | $19.00 | $16.30 | -14.21% |
u – unit offering |